According to a report by Reuters on Wednesday, New Jersey-based Amicus Therapeutics Inc. (NASDAQ:FOLD) announced that in a 24-month trial, its new drug migalastat was effective at reducing abnormal fat accumulation in kidney cells compared with placebo. The drug is being considered alone and in combination therapy for treating Fabry disease, a congenital disorder that can be debilitating and even fatal. Amicus Therapeutics, Inc. (NASDAQ:FOLD) … Continue reading Micro-cap Most Volatile Stocks: Amicus Therapeutics (NASDAQ:FOLD), Synthetic Biologics Inc (NYSEMKT:SYN), IsoRay (NYSEMKT:ISR), Ultra Clean (NASDAQ:UCTT)